Marker: Clinical Program Updates and Pipeline Prioritization

 Strategic prioritization of clinical programs with focus on MT-601 in patients with lymphoma

MultiTAA-specific T cell therapies demonstrate clinical safety and positive clinical data across multiple indications

Marker provides updates supporting the clinical benefits of MT-401 in patients with measurable residual disease (MRD)

https://www.biospace.com/article/releases/marker-therapeutics-announces-clinical-program-updates-and-pipeline-prioritization/